Table 4.

Impact of pre-emptive TIPS (vs. drug plus endoscopic treatment) on 1-year mortality in individuals with Child-Pugh B cirrhosis according to different risk classification rules.

Risk classification	No. of patients (%)	Univariable models Unadjusted estimates			Multivariable models adjusted for the baseline predictive variables
		HR∗ (95%CI)	p value	p for interaction	HR∗ (95%CI)	p value	p for interaction	Variables adjusted for‡
CLIF-C ADs 48-56				0.064			0.176
<48	607 (59.4%)	1.05 (0.63 to 1.75)	0.074		1.10 (0.63 to 1.90)	0.740		Age, WBC, bilirubin, albumin, creatinine, PLT, HCC
48-56	302 (29.6%)	0.49 (0.27 to 0.90)	0.019		0.48 (0.26 to 0.88)	0.018		Age, active bleeding, bilirubin, PLT, comorbidities
>56	112 (11.0%)	0.42 (0.20 to 0.86)	0.012		0.41 (0.18 to 0.91)	0.028		Age, WBC, INR, bilirubin, albumin, creatinine, HCC
Active bleeding				0.059			0.063
No	698 (68.4%)	0.83 (0.54 to 1.30)	0.512		0.80 (0.53 to 1.29)	0.393		Age, INR, bilirubin, albumin, creatinine, sodium
Yes	323 (31.6%)	0.43 (0.25 to 0.73)	0.001		0.43 (0.25 to 0.75)	0.003		INR, bilirubin, creatinine, PLT, comorbidities, HCC
Child B 8-9+AB criteria¶				0.006			0.009
Low risk	828 (81.1%)	0.82 (0.55 to 1.23)	0.413		0.80 (0.53 to 1.21)	0.292		Age, INR, bilirubin, albumin, creatinine, comorbidities
High risk	193 (18.9%)	0.29 (0.15 to 0.56)	<0.001		0.36 (0.18 to 0.70)	0.002		Age, creatinine, PLT

AB, active bleeding, CLIF-C ADs, Chronic Liver Failure-Consortium acute decompensation score; HCC, hepatocellular carcinoma; HR, hazard ratio; INR, international normalised ratio; PLT, platelet count; WBC, white blood cell.

^∗HR for the effect of p-TIPS vs. drug plus endoscopic treatment (as reference).

^‡We adjusted these variables based on their associations with the outcomes of interest or a change in effect estimates of more than 10%.

^¶Child B8-9+AB criteria: Low risk: Child-Pugh B without active bleeding and Child-Pugh B7 with active bleeding; High risk: Child-Pugh B8-9 with active bleeding at endoscopy.